Stuck in the Window with You: HIV Exposure Prophylaxis in the Highest Risk People who Inject Drugs

Abstract

The opioid and polysubstance epidemics could drive a surge in new HIV infections among people who inject drugs (PWID). Longstanding strategies to reduce HIV incidence, including syringe service programs, condom distribution, medications for opioid use disorder, and low-barrier HIV testing and treatment have not been adequate to eliminate transmission in this population. Although HIV pre-exposure prophylaxis (PrEP) is an evidence-based intervention that reduces HIV incidence among PWID, uptake in PWID has lagged due to limited PrEP knowledge, discrepancies between perceived and actual HIV risk, stigma, and structural barriers to adherence including homelessness and incarceration. In our efforts to deploy PrEP to PWID in our low-barrier substance use disorder bridge clinic, we have encountered another barrier: the HIV testing window period. We discuss challenges in delivering HIV exposure prophylaxis to the highest risk PWID, our current approach, and the need for more data to guide best practices.

Keywords

HIV prevention PrEP PEP people who inject drugs opioid use disorder injection drug use

Get full access to this article

View all access options for this article.

References

Cranston

. Notes from the field: HIV diagnoses among persons who inject drugs — Northeastern Massachusetts. MMWR Morb Mortal Wkly Rep. 2019;68:2015–2018. Available at: https://www-cdc-gov.ezproxy.bu.edu/mmwr/volumes/68/wr/mm6810a6.htm. Accessed June 6 2019.

Evans

. Notes from the field: HIV infection investigation in a rural area — West Virginia, 2017. MMWR Morb Mortal Wkly Rep. 2018;67:257–258. Available at: https://www.cdc.gov/mmwr/volumes/67/wr/mm6708a6.htm. Accessed August 5, 2019.

Peters

, Pontones

, Hoover

, . HIV infection linked to injection use of oxymorphone in Indiana, 2014–2015. N Engl J Med. 2016;375(3):229–239.

Golden MR , Lechtenberg

, Glick

, . Outbreak of human immunodeficiency virus infection among heterosexual persons who are living homeless and inject drugs – Seattle, Washington, 2018. MMWR Morb Mortal Wkly Rep. 2019;68(15):344–349.

Centers for Disease Control and Prevention. HIV Surveillance Report. Vol. 29. 2017. http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html. Published November 2018. Accessed October 3, 2019.

Burnett

. HIV infection and HIV-associated behaviors among persons who inject drugs — 20 cities, United States, 2015. MMWR Morb Mortal Wkly Rep. 2018;67:23–28. Available at: https://www.cdc.gov/mmwr/volumes/67/wr/mm6701a5.htm. Accessed July 31, 2019.

Spiller

, Broz

, Wejnert

, Nerlander

, Paz-Bailey

. HIV infection and HIV-associated behaviors among persons who inject drugs — 20 cities, United States, 2012. MMWR Morb Mortal Wkly Rep. 2015;64(10):270–275.

Hess

, Hu

, Lansky

, Mermin

, Hall

. Lifetime risk of a diagnosis of HIV infection in the United States. Ann Epidemiol. 2017;27(4):238–243.

Choopanya

, Martin

, Suntharasamai

, . Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083–2090.

10.

Centers for Disease Control and Prevention. Preexposure prophylaxis for the prevention of HIV infection in the United States – 2017 update: a clinical practice guideline. 2018. Available at: https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf. Accessed August 5, 2019.

11.

Bazzi

, Biancarelli

, Childs

, . Limited knowledge and mixed interest in pre-exposure prophylaxis for HIV prevention among people who inject drugs. AIDS Patient Care STDs. 2018;32(12):529–537.

12.

Edelman

, Moore

, Calabrese

, . Primary care physicians’ willingness to prescribe HIV pre-exposure prophylaxis for people who inject drugs. AIDS Behav. 2017;21(4):1025–1033.

13.

Branson

, Stekler

. Detection of acute HIV infection: we can't close the window. J Infect Dis. 2012;205(4):521–524.

14.

Centers for Disease Control and Prevention. Updated guidelines for antiretroviral postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV—United States, 2016. Ann Emerg Med. 2016;68:335–338.